We hypothesized that intralesional targeting of therapeutic molecules using blood‐born cells could be a clinically relevant strategy to stimulate remyelination in demyelinating CNS diseases, such as MS, by means of targeting the expression of Sema3F to demyelinating lesions and increasing OPC recruitment. The gene discussed is SEMA3F; the disease is myeloid sarcoma.